基于卒中或TIA后基线风险分层评估吡格列酮疗效
该研究为IRIS试验的二次分析,纳入3876例缺血性卒中或TIA伴胰岛素抵抗患者,按基线5年卒中或心梗风险中位数分层。结果显示,高风险患者使用吡格列酮的绝对风险下降更大(-4.9% vs -1.9%),但骨折风险也更高。
要点
- 高风险患者吡格列酮绝对获益更大(5年风险降4.9%)
- 低风险患者绝对获益较小(5年风险降1.9%)
- 吡格列酮在高风险患者中增重较少但骨折风险更高
核心结论
- 缺血性卒中或TIA后,基线卒中或心梗风险较高的患者从吡格列酮治疗中获得的绝对获益更大,但骨折风险也更高。
研究设计与样本
- IRIS试验的二次分析,为双盲、安慰剂对照试验,纳入179个中心、7个国家的3876例缺血性卒中或TIA伴胰岛素抵抗患者,平均随访4.1年。
主要发现
- 低风险组5年卒中或心梗风险:吡格列酮组6.0% vs 安慰剂组7.9%,绝对风险差-1.9%(95%CI -4.4%至0.6%)。
- 高风险组5年卒中或心梗风险:吡格列酮组14.7% vs 安慰剂组19.6%,绝对风险差-4.9%(95%CI -8.6%至1.2%)。
- 吡格列酮在高风险患者中增重较少,但骨折风险增加更多。
关键数值与推荐
- 5年卒中或心梗风险中位数分层:低风险组吡格列酮组6.0% vs 安慰剂7.9%;高风险组14.7% vs 19.6%。
- 绝对风险差:低风险组-1.9%(95%CI -4.4%至0.6%),高风险组-4.9%(95%CI -8.6%至1.2%)。
临床怎么用
- 对缺血性卒中或TIA伴胰岛素抵抗的患者,可依据基线风险分层选择吡格列酮,高风险者绝对获益更大但需监测骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is growing recognition that patients may respond differently to therapy and that the average treatment effect from a clinical trial may not apply equally to all candidates for a therapy. OBJECTIVE: To determine whether, among patients with an ischemic stroke or transient ischemic attack and insulin resistance, those at higher risk for future stroke or myocardial infarction (MI) derive more benefit from the insulin-sensitizing drug pioglitazone hydrochloride compared with patients at lower risk. DESIGN, SETTING, AND PARTICIPANTS: A secondary analysis was conducted of the Insulin Resistance Intervention After Stroke trial, a double-blind, placebo-controlled trial of pioglitazone for secondary prevention. Patients were enrolled from 179 research sites in 7 countries from February 7, 2005, to January 15, 2013, and were followed up for a mean of 4.1 years through the study's end on July 28, 2015. Eligible participants had a qualifying ischemic stroke or transient ischemic attack within 180 days of entry and insulin resistance without type 1 or type 2 diabetes. INTERVENTIONS: Pioglitazone or matching placebo. MAIN OUTCOMES AND MEASURES: A Cox proportional hazards regression model was created using baseline features to stratify patients above or below the median risk for stroke or MI within 5 years. Within each stratum, the efficacy of pioglitazone for preventing stroke or MI was calculated. Safety outcomes were death, heart failure, weight gain, and bone fracture. RESULTS: Among 3876 participants (1338 women and 2538 men; mean [SD] age, 63 [11] years), the 5-year risk for stroke or MI was 6.0% in the pioglitazone group among patients at lower baseline risk compared with 7.9% in the placebo group (absolute risk difference, -1.9% [95% CI, -4.4% to 0.6%]). Among patients at higher risk, the risk was 14.7% in the pioglitazone group vs 19.6% for placebo (absolute risk difference, -4.9% [95% CI, -8.6% to 1.2%]). Hazard ratios were similar for patients below or above the median risk (0.77 vs 0.75; P = .92). Pioglitazone increased weight less among patients at higher risk but increased the risk for fracture more. CONCLUSIONS AND RELEVANCE: After an ischemic stroke or transient ischemic attack, patients at higher risk for stroke or MI derive a greater absolute benefit from pioglitazone compared with patients at lower risk. However, the risk for fracture is also higher. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00091949.
引用
- Kernan WN, Viscoli CM, Dearborn JL, et al. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurol. 2017. PMID: 28975241. doi:10.1001/jamaneurol.2017.2136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。